ReviewJournal of cardiovascular translational research2020
Exosomes: Cell-Free Therapy for Cardiovascular Diseases.
Review in Journal of cardiovascular translational research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Progress in research on the role of exosomal miRNAs in the diagnosis and treatment of cardiovascular diseases.Frontiers in genetics · 2022Pooled it
- Empowering Extracellular Vesicle Wound Therapy via Local Drug Delivery Systems: Mechanistic Insights and Advanced Stimuli-Responsive Strategies.Gels (Basel, Switzerland) · 2026Review
- From Adipose Tissue to Cardiac Repair: Extracellular Vesicles in Cardiovascular Regeneration.Journal of cellular and molecular medicine · 2026Review
- Extracellular vesicles derived from differentiated granulosa-like cells restore the ovarian function of rats with premature ovarian insufficiency.Stem cells translational medicine · 2026Article
- Exosome-based therapies for inflammatory disorders: a review of recent advances.Stem cell research & therapy · 2024Review
- Exosomal miRNA-21-5p and miRNA-21-3p as key biomarkers of myocardial infarction.Health science reports · 2024Article
- Biomimetic nanomaterials in myocardial infarction treatment: Harnessing bionic strategies for advanced therapeutics.Materials today. Bio · 2024Review
- Exosomes from preconditioned mesenchymal stem cells: Tissue repair and regeneration.Regenerative therapy · 2024Review
- Mesenchymal Stem Cell-Derived Exosomes Ameliorate Doxorubicin-Induced Cardiotoxicity.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Engineered exosomes in emerging cell-free therapy.Frontiers in oncology · 2024Review
- The Landscape of Exosomes Biogenesis to Clinical Applications.International journal of nanomedicine · 2024Review
- Global Research Trends on Exosome in Cardiovascular Diseases: A Bibliometric-Based Visual Analysis.Vascular health and risk management · 2024Review
- Targeted drug delivery of engineered mesenchymal stem/stromal-cell-derived exosomes in cardiovascular disease: recent trends and future perspectives.Frontiers in bioengineering and biotechnology · 2024Review
- Unraveling the Multifaceted Roles of Extracellular Vesicles: Insights into Biology, Pharmacology, and Pharmaceutical Applications for Drug Delivery.International journal of molecular sciences · 2023Review
- The Immunomodulatory Role of Cell-Free Approaches in SARS-CoV-2-Induced Cytokine Storm-A Powerful Therapeutic Tool for COVID-19 Patients.Biomedicines · 2023Review
- Exosomes in Myocardial Infarction: Therapeutic Potential and Clinical Application.Journal of cardiovascular translational research · 2023Review
- Mending a broken heart by biomimetic 3D printed natural biomaterial-based cardiac patches: a review.Frontiers in bioengineering and biotechnology · 2023Review
- The Roles of Exosomes upon Metallic Ions Stimulation in Bone Regeneration.Journal of functional biomaterials · 2022Review
- Plasma-derived exosomes implement miR-126-associated regulation of cytokines secretion in PBMCs of CHF patients in vitro.Acta bio-medica : Atenei Parmensis · 2022Article
- Delivery of engineered extracellular vesicles with miR-29b editing system for muscle atrophy therapy.Journal of nanobiotechnology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases (CVDs) are an important cause of death and disease worldwide. Because injured cardiac tissue cannot be repaired itself, it is urgent to develop other alternate therapies. Stem cells can be differentiated into cardiomyocytes, endothelial cells, and vascular smooth muscle cells for the treatment of CVDs. Therefore, cell therapy has recently been considered a viable treatment option that can significantly improve cardiac function. Nonetheless, implanted stem cells rarely survive in the recipient heart, suggesting that the benefits of stem cell therapy may involve other mechanisms. Exosomes derived from stem cells have a myocardial protection function after myocardial injury, and may be a promising and effective therapy for CVDs. Here, we discuss the application and mechanism of exosomes derived from stem cells in the diagnosis and treatment of CVDs and provide evidence for the application of exosomes in CVDs. Graphical Abstract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.